Loading...

KPL Kwality Pharmaceuticals Ltd Other Situations Announcement

Kwlt

KPL

Kwality Pharmaceuticals Ltd

(KPL)

2025 Announcement

Show Summary

Summary

Compliance Certificate

Investor Presentation

Annual Compliance Report

Financial Results Published

Regulatory Audit Success

Regulatory Compliance

Compliance Certificate

Product Registration

Financial Results

Compliance Certificate

RCGM Approval Granted

Tamoxifen Approval

Investor Meeting

New Product Approval

EU Market Entry

Financial Results Released

SEBI Compliance Certificate

Auditor Appointment

Annual General Meeting

Book Closure Notice

Price Movement Clarification

Financial Results

Approval Received

Certificate Compliance

Compliance Submission

Newspaper Publication

Investor Presentation

Investor Presentation

Certificate Submission

Approval Announcement

INVIMA Approval

Compliance Certificate

Certificate Submission

Certificate Submission

Non-Applicability Disclosure

AGM Delay Clarification

Certificate Submission

Disclosure of Related Party...

Certificate Submission

Resumption of Operations Af...

Accident at Amritsar Plant

Board Meeting Outcome

Investor Conferences

Financial Statements

Appointments, Resignations,...

Earnings Releases

Related Party Transactions

External Links:

Data:

Kwality Pharmaceuticals has received RCGM approval to begin pre-clinical studies for its Erythropoietin product (10,000 IU/mL), marking a major step in expanding its biologics portfolio.

AI Assistant

Kwality Pharmaceuticals Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.